Clinical, imaging, and pathological heterogeneity of the

Citation Report

#	Article	IF	Citations
1	Early-onset dementias: diagnostic and etiological considerations. Alzheimer's Research and Therapy, 2013, 5, S7.	3.0	47
2	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimer's Research and Therapy, 2013, 5, S8.	3.0	17
3	Biomarker-Driven Therapeutic Management of Alzheimer's Disease: Establishing the Foundations. Clinical Pharmacology and Therapeutics, 2013, 95, 67-77.	2.3	19
4	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. , 2014, 04, .		17
5	Lead Discovery for Alzheimer's Disease Related Target Protein RbAp48 from Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-14.	0.9	9
6	CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer's disease. Journal of the Neurological Sciences, 2014, 339, 91-96.	0.3	23
7	Biomarker Modelling of Early Molecular Changes in Alzheimer's Disease. Molecular Diagnosis and Therapy, 2014, 18, 213-227.	1.6	4
8	Interactions of buttermilk with curcuminoids. Food Chemistry, 2014, 149, 47-53.	4.2	33
9	Back to the future: Alzheimer's disease heterogeneity revisited. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 368-370.	1.2	33
10	Linguistic Features Identify Alzheimer's Disease in Narrative Speech. Journal of Alzheimer's Disease, 2015, 49, 407-422.	1.2	439
11	Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers. Journal of Alzheimer's Disease, 2016, 49, 1143-1159.	1.2	61
12	Mating and Memory: An Educational Primer for Use with "Epigenetic Control of Learning and Memory in Drosophila by Tip60 HAT Action". Genetics, 2015, 200, 21-28.	1.2	3
13	Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity. Degenerative Neurological and Neuromuscular Disease, 2015, 5, 9.	0.7	4
14	Gaussian process classification of Alzheimer's disease and mild cognitive impairment from resting-state fMRI. NeuroImage, 2015, 112, 232-243.	2.1	152
15	Amyloid Polymorphism: Structural Basis and Neurobiological Relevance. Neuron, 2015, 86, 632-645.	3.8	347
16	Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor Î³ Agonist Treatment Reduces Amyloid Î² Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. Journal of Biological Chemistry, 2015, 290, 21591-21602.	1.6	71
17	Specific Features of Executive Dysfunction in Alzheimer-Type Mild Dementia Based on Computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) Test Results. Medical Science Monitor, 2016, 22, 3605-3613.	0.5	10
18	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. Journal of Neurochemistry, 2016, 139, 224-236.	2.1	17

#	Article	IF	Citations
19	Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. Brain, 2017, 140, aww319.	3.7	114
20	Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiology of Aging, 2016, 47, 149-156.	1.5	39
21	Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6535-E6544.	3.3	137
22	Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective. Brain Pathology, 2016, 26, 664-671.	2.1	5
23	Reducing Endogenous Î±-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. Journal of Neuroscience, 2016, 36, 7971-7984.	1.7	44
24	Tool use disorders in neurodegenerative diseases: Roles of semantic memory and technical reasoning. Cortex, 2016, 82, 119-132.	1.1	38
25	Neurodegenerative disorders share common features of â€œloss of functionâ€•states of a proposed mechanism of nervous system functions. Biomedicine and Pharmacotherapy, 2016, 83, 412-430.	2.5	18
26	Protective effects of salicylate on PKA inhibitor (H-89)-induced spatial memory deficit via lessening autophagy and apoptosis in rats. Pharmacology Biochemistry and Behavior, 2016, 150-151, 158-169.	1.3	3
27	Spontaneous confabulations in amnestic-mild cognitive impairment due to Alzheimer's disease: a new (yet old) atypical variant?. Neurocase, 2016, 22, 451-460.	0.2	4
28	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. Neurobiology of Aging, 2016, 42, 124-131.	1.5	29
29	When a Little Knowledge Can Be Dangerous: False-Positive Diagnosis of Behavioral Variant Frontotemporal Dementia among Community Clinicians. Dementia and Geriatric Cognitive Disorders, 2016, 41, 99-108.	0.7	33
30	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
31	FRONTIER Executive Screen: a brief executive battery to differentiate frontotemporal dementia and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 831-835.	0.9	24
32	Mitochondrial Proteome Changes Correlating with Î²-Amyloid Accumulation. Molecular Neurobiology, 2017, 54, 2060-2078.	1.9	17
33	Tau PET imaging: present and future directions. Molecular Neurodegeneration, 2017, 12, 19.	4.4	220
34	Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology, 2017, 88, 1431-1438.	1.5	46
35	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. Journal of Clinical Movement Disorders, 2017, 4, 2.	2.2	27
36	Effectiveness of cognition-focused interventions in activities of daily living performance in people with dementia: A systematic review. British Journal of Occupational Therapy, 2017, 80, 397-408.	0.5	5

#	Article	IF	Citations
37	Stem Cell Technology for (Epi)genetic Brain Disorders. Advances in Experimental Medicine and Biology, 2017, 978, 443-475.	0.8	5
38	The effect of repetitive subconcussive collisions on brain integrity in collegiate football players over a single football season: A multi-modal neuroimaging study. NeuroImage: Clinical, 2017, 14, 708-718.	1.4	127
39	Proteomics Analysis of Blood Serums from Alzheimerâ€™s Disease Patients Using iTRAQ Labeling Technology. Journal of Alzheimer's Disease, 2017, 56, 361-378.	1.2	64
40	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	1.4	23
41	The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?. Metabolic Brain Disease, 2017, 32, 1335-1355.	1.4	57
42	Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 6763.	1.6	64
43	Individual differences in cognitive neuropsychology. Personality and Individual Differences, 2017, 118, 4-6.	1.6	1
44	18F PET with florbetapir for the early diagnosis of Alzheimerâ€™s disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library, 2017, 2017, CD012216.	1.5	32
45	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	3.3	170
46	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimerâ€™s disease. European Radiology, 2017, 27, 1169-1175.	2.3	97
47	Study on synthesis and properties of nanoparticles loaded with amaryllidaceous alkaloids. Open Life Sciences, 2017, 12, 356-364.	0.6	2
48	A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults. Clinical Interventions in Aging, 2017, Volume 12, 2123-2130.	1.3	4
49	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Diseaseâ€"From Brain Starch to Bench and Bedside. Diagnostics, 2017, 7, 42.	1.3	19
50	Trehalose protects against cadmium-induced cytotoxicity in primary rat proximal tubular cells via inhibiting apoptosis and restoring autophagic flux. Cell Death and Disease, 2017, 8, e3099-e3099.	2.7	101
51	Studies for Improving a Rat Model of Alzheimerâ€™s Disease: Icv Administration of Well-Characterized Î²-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory. Molecules, 2017, 22, 2007.	1.7	56
52	Enfermedad de Alzheimer de inicio precoz y de inicio tardÃo: Â¿son la misma entidad?. NeurologÃa, 2018, 33, 244-253.	0.3	52
53	Blood-based immunoassay of tau proteins for early diagnosis of Alzheimer's disease using surface plasmon resonance fiber sensors. RSC Advances, 2018, 8, 7855-7862.	1.7	38
54	Cerebrospinal Fluid Biomarkers of Preclinical Alzheimerâ€™s Disease. Neuromethods, 2018, , 93-106.	0.2	1

#	Article	IF	Citations
55	Coexisting order and disorder within a common 40-residue amyloid-Î² fibril structure in Alzheimer's disease brain tissue. Chemical Communications, 2018, 54, 5070-5073.	2.2	26
56	Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau. Journal of Alzheimer's Disease, 2018, 61, 1201-1219.	1.2	4
57	Differential Contributions of Selective Attention and Sensory Integration to Driving Performance in Healthy Aging and Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2018, 24, 486-497.	1.2	9
58	Structural heterogeneity and intersubject variability of AÎ² in familial and sporadic Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E782-E791.	3.3	105
59	Dissociable influences of <i>APOE</i> Îµ4 and polygenic risk of AD dementia on amyloid and cognition. Neurology, 2018, 90, e1605-e1612.	1.5	71
60	Early- and late-onset Alzheimer disease: Are they the same entity?. NeurologÃa (English Edition), 2018, 33, 244-253.	0.2	27
61	AÎ² propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
62	Alzheimersâ€™ disease and caregiving: a meta-analytic review comparing the mental health of primary carers to controls. Aging and Mental Health, 2018, 22, 1395-1405.	1.5	74
63	Alzheimer's disease. European Journal of Neurology, 2018, 25, 59-70.	1.7	1,624
64	Insulin-Degrading Enzyme in the Fight against Alzheimerâ€™s Disease. Trends in Pharmacological Sciences, 2018, 39, 49-58.	4.0	133
65	Topographic Markers Drive Proteinopathies to Selection of Target Brain Areas at Onset in Neurodegenerative Dementias. Frontiers in Aging Neuroscience, 2018, 10, 308.	1.7	4
66	Questions concerning the role of amyloid-Î² in the definition, aetiology and diagnosis of Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
67	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	3.7	102
68	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
69	Modeling and prediction of clinical symptom trajectories in Alzheimerâ€™s disease using longitudinal data. PLoS Computational Biology, 2018, 14, e1006376.	1.5	88
70	Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 629-637.	1.2	21
71	<i>APOE</i> â€Îµ4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 1137-1147.	0.4	39
72	A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	20

#	Article	IF	Citations
73	Validity of the QUADAS-2 in Assessing Risk of Bias in Alzheimer's Disease Diagnostic Accuracy Studies. Frontiers in Psychiatry, 2018, 9, 221.	1.3	10
74	Increased Amplitude of the P3a ERP Component as a Neurocognitive Marker for Differentiating Amnestic Subtypes of Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 19.	1.7	18
75	A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease. GigaScience, 2018, 7, .	3.3	5
76	Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease. Scientific Reports, 2018, 8, 7490.	1.6	97
77	A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation. Dementia and Neurocognitive Disorders, 2019, 18, 33.	0.4	20
78	The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32.	4.4	1,497
79	Does the Right Focal Variant of Alzheimer's Disease Really Exist? A Literature Analysis. Journal of Alzheimer's Disease, 2019, 71, 405-420.	1.2	6
80	Detecting Alzheimer's Disease from Continuous Speech Using Language Models. Journal of Alzheimer's Disease, 2019, 70, 1163-1174.	1.2	19
81	Associations Between Depression, Traumatic Brain Injury, and Cognitively-Defined Late-Onset Alzheimer's Disease Subgroups. Journal of Alzheimer's Disease, 2019, 70, 611-619.	1.2	7
82	Using data science to diagnose and characterize heterogeneity of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 264-271.	1.8	12
83	Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. NeuroImage, 2019, 201, 116043.	2.1	38
84	An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures. Journal of Psychiatry and Neuroscience, 2019, 44, 246-250.	1.4	35
85	Alzheimer's disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathologica, 2019, 138, 597-612.	3.9	75
86	Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1112-1123.	0.9	34
87	Elevations in Serum Dickkopf-1 and Disease Progression in Community-Dwelling Older Adults With Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 278.	1.7	11
88	Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 364-373.	1.8	11
89	Advances in Management of Psychosis in Neurodegenerative Diseases. Current Treatment Options in Neurology, 2019, 21, 3.	0.7	10
90	Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. International Journal of Pharmaceutics, 2019, 559, 360-372.	2.6	132

#	Article	IF	Citations
91	Co-expression Network Analysis Revealing the Potential Regulatory Roles of lncRNAs in Alzheimer's Disease. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 645-654.	2.2	20
92	Proteomic signatures of neuroinflammation in Alzheimer's disease, multiple sclerosis and ischemic stroke. Expert Review of Proteomics, 2019, 16, 601-611.	1.3	14
93	Riemannian Geometry Learning for Disease Progression Modelling. Lecture Notes in Computer Science, 2019, , 542-553.	1.0	25
94	ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology. PLoS Biology, 2019, 17, e3000313.	2.6	25
95	α-synuclein in the pathophysiology of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 23.	4.4	197
96	Frontal variant of Alzheimer's disease masquerading as behavioural-variant frontotemporal dementia: a case study comparison. Neurocase, 2019, 25, 48-58.	0.2	12
97	Prion and Prion-Like Protein Strains: Deciphering the Molecular Basis of Heterogeneity in Neurodegeneration. Viruses, 2019, 11, 261.	1.5	41
98	An Overview of Primary Dementias as Clinicopathological Entities. Seminars in Neurology, 2019, 39, 153-166.	0.5	13
99	Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by <i>MAPT</i> N279K mutation in relation to tau positron emission tomography features. Movement Disorders, 2019, 34, 568-574.	2.2	18
100	Deep learning for clustering of multivariate clinical patient trajectories with missing values. GigaScience, 2019, 8, .	3.3	31
101	AmpliSeq Transcriptome of Laser Captured Neurons from Alzheimer Brain: Comparison of Single Cell Versus Neuron Pools. , 2019, 10, 1146.		5
102	Altered Neurochemistry in Alzheimer's Disease: Targeting Neurotransmitter Receptor Mechanisms and Therapeutic Strategy. Neurophysiology, 2019, 51, 293-309.	0.2	21
103	Impairments of attention in Alzheimer's disease. Current Opinion in Psychology, 2019, 29, 41-48.	2.5	23
104	A case of right Alzheimer's disease. Aging Clinical and Experimental Research, 2019, 31, 733-737.	1.4	4
105	Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. Molecular Psychiatry, 2020, 25, 2942-2951.	4.1	57
106	Applications of machine learning to brain disorders. , 2020, , 45-65.		7
107	The Structural Basis of Amyloid Strains in Alzheimer's Disease. ACS Biomaterials Science and Engineering, 2020, 6, 2498-2505.	2.6	9
108	Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. GeroScience, 2020, 42, 1499-1525.	2.1	64

#	Article	IF	Citations
109	Identifying diagnosis-specific genotype–phenotype associations via joint multitask sparse canonical correlation analysis and classification. Bioinformatics, 2020, 36, i371-i379.	1.8	20
110	ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain, 2020, 143, 2295-2311.	3.7	24
111	Association of <i>APOE4</i> and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.5	73
112	The Two-Step Strategy Could Be Inadequate and Counteracting to Diagnose Prodromal Dementia or Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2020, 12, 229.	1.7	3
113	A grounded theory study to identify caregiving phases and support needs across the Alzheimer's disease trajectory. Disability and Rehabilitation, 2022, 44, 1050-1059.	0.9	21
114	The existence of $A\beta$ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
115	Neuropathological assessment of the Alzheimer spectrum. Journal of Neural Transmission, 2020, 127, 1229-1256.	1.4	34
116	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	3.0	13
117	Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology. Scientific Reports, 2020, 10, 14579.	1.6	29
118	Posterior Cingulate Cortex Hypometabolism in Non-Amnestic Variants of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1569-1577.	1.2	7
119	The role of the cellular prion protein in the uptake and toxic signaling of pathological neurodegenerative aggregates. Progress in Molecular Biology and Translational Science, 2020, 175, 297-323.	0.9	5
120	Early-onset dementia: key issues using a relationship-centred care approach. Postgraduate Medical Journal, 2021, 97, 598-604.	0.9	15
121	A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. Trials, 2020, 21, 1016.	0.7	0
122	Identifying novel associations in GWAS by hierarchical Bayesian latent variable detection of differentially misclassified phenotypes. BMC Bioinformatics, 2020, 21, 178.	1.2	7
123	Diffusion MRI detects early brain microstructure abnormalities in 2-month-old 3×-Tg-AD mice. NMR in Biomedicine, 2020, 33, e4346.	1.6	11
124	Biological subtypes of Alzheimer disease. Neurology, 2020, 94, 436-448.	1.5	210
125	Identifying a subtype of Alzheimer's disease characterised by predominant right focal cortical atrophy. Scientific Reports, 2020, 10, 7256.	1.6	5
126	Deep ensemble learning for Alzheimer's disease classification. Journal of Biomedical Informatics, 2020, 105, 103411.	2.5	95

#	Article	IF	Citations
127	Possible clinical anatomical features of right Alzheimer's disease (RAD). Aging Clinical and Experimental Research, 2021, 33, 669-671.	1.4	2
128	The interaction of insoluble Amyloid-β with soluble Amyloid-β dimers decreases Amyloid-β plaque numbers. Neuropathology and Applied Neurobiology, 2021, 47, 603-610.	1.8	3
129	A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). NeuroImage: Clinical, 2021, 29, 102527.	1.4	19
130	Severity Distribution of Alzheimer's Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. Journal of Alzheimer's Disease, 2021, 79, 807-817.	1.2	18
131	Preexisting dementia is associated with higher mortality rate in patients with femoral neck fracture. Aging Medicine (Milton (N S W)), 2021, 4, 12-18.	0.9	4
132	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	1.4	13
133	The biological pathways of Alzheimer disease: a review. AIMS Neuroscience, 2021, 8, 86-132.	1.0	111
134	Modified Snake α-Neurotoxin Averts β-Amyloid Binding to α7 Nicotinic Acetylcholine Receptor and Reverses Cognitive Deficits in Alzheimer's Disease Mice. Molecular Neurobiology, 2021, 58, 2322-2341.	1.9	6
135	Intranasal drug delivery for treatment of Alzheimer's disease. Drug Delivery and Translational Research, 2021, 11, 411-425.	3.0	34
136	Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 1-27.	1.2	27
137	Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 735-747.	1.2	1
138	Amyloid pathology arrangements in Alzheimer's disease brains modulate in vivo seeding capability. Acta Neuropathologica Communications, 2021, 9, 56.	2.4	15
139	A Review of Brain Atrophy Subtypes Definition and Analysis for Alzheimer's Disease Heterogeneity Studies. Journal of Alzheimer's Disease, 2021, 80, 1339-1352.	1.2	19
140	Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. Clinical and Translational Medicine, 2021, 11, e397.	1.7	22
141	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. Brain, 2021, 144, 2946-2953.	3.7	46
142	Language Impairment in Alzheimer's Disease—Robust and Explainable Evidence for AD-Related Deterioration of Spontaneous Speech Through Multilingual Machine Learning. Frontiers in Aging Neuroscience, 2021, 13, 642033.	1.7	21
144	The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Scientific Reports, 2021, 11, 13050.	1.6	12
146	N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 708119.	1.4	9

#	Article	IF	Citations
147	Heterogeneous effects of genetic risk for Alzheimer's disease on the phenome. Translational Psychiatry, 2021, 11, 406.	2.4	4
149	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346.	5.0	74
150	Deep Convolutional Neural Networks With Ensemble Learning and Generative Adversarial Networks for Alzheimer's Disease Image Data Classification. Frontiers in Aging Neuroscience, 2021, 13, 720226.	1.7	30
151	Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease. European Journal of Nutrition, 2022, 61, 589-604.	1.8	33
152	High-Definition Transcranial Direct Current Stimulation Improves Delayed Memory in Alzheimer's Disease Patients: A Pilot Study Using Computational Modeling to Optimize Electrode Position. Journal of Alzheimer's Disease, 2021, 83, 753-769.	1.2	13
153	Preliminary validation of the apraxia battery for adults-second edition (ABA-2) in Greek patients with dementia. Acta Neurologica Belgica, 2021, , 1.	0.5	0
154	Heterogeneity and Factorial Structure in Alzheimer's Disease: A Cognitive Perspective. Journal of Alzheimer's Disease, 2021, 83, 1341-1351.	1.2	7
155	Diffusion MRI detects basal forebrain cholinergic abnormalities in the 3xTg-AD mouse model of Alzheimer's disease. Magnetic Resonance Imaging, 2021, 83, 1-13.	1.0	14
156	Diagnostic biomarkers in Alzheimer's disease. Biomarkers in Neuropsychiatry, 2021, 5, 100041.	0.7	12
157	Personalized brain models identify neurotransmitter receptor changes in Alzheimer's disease. Brain, 2022, 145, 1785-1804.	3.7	23
158	Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders. Translational Psychiatry, 2020, 10, 107.	2.4	29
159	On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. Prion, 2020, 14, 257-270.	0.9	15
160	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
166	Pathobiological Subtypes of Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2020, 49, 321-333.	0.7	33
167	Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease. Medical Science Monitor, 2015, 21, 3887-3899.	0.5	9
168	Childhood Learning Disabilities and Atypical Dementia: A Retrospective Chart Review. PLoS ONE, 2015, 10, e0129919.	1.1	16
169	Alzheimer's disease as a systems network disorder: chronic stress/dyshomeostasis, innate immunity, and genetics. Aging, 2020, 12, 17815-17844.	1.4	9
170	<p>Physiological Vibration Acceleration (Phybrata) Sensor Assessment of Multi-System Physiological Impairments and Sensory Reweighting Following Concussion</p>. Medical Devices: Evidence and Research, 2020, Volume 13, 411-438.	0.4	5

#	Article	IF	Citations
171	Key Peptides and Proteins in Alzheimer's Disease. Current Protein and Peptide Science, 2019, 20, 577-599.	0.7	30
172	The Association between Polygenic Hazard and Markers of Alzheimer's Disease Following Stratification for APOE Genotype. Current Alzheimer Research, 2020, 17, 667-679.	0.7	2
173	Long-term acupuncture treatment has a multi-targeting regulation on multiple brain regions in rats with Alzheimer's disease: a positron emission tomography study. Neural Regeneration Research, 2017, 12, 1159.	1.6	17
174	Structural Correlates of Depressive Symptoms in Prodromal Alzheimer's Disease. British Journal of Medicine and Medical Research, 2016, 14, 1-10.	0.2	3
175	Improvement of Machine Learning Models' Performances based on Ensemble Learning for the detection of Alzheimer Disease. , 2021, , .		11
176	Pairwise Correlation Analysis of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset Reveals Significant Feature Correlation. Genes, 2021, 12, 1661.	1.0	5
177	Application of a multi-component cyclocondensation to develop a bioactive molecular scaffold. European Journal of Chemistry, 2016, 7, 135-136.	0.3	0
179	Biomarkers of Alzheimer's Disease. Mental Health and Illness Worldwide, 2017, , 1-35.	0.1	0
180	Biomarkers of Alzheimer's Disease. Mental Health and Illness Worldwide, 2017, , 105-139.	0.1	0
183	Measurement Challenges in Research With Individuals With Cognitive Impairment. Research in Gerontological Nursing, 2019, 12, 7-15.	0.2	5
188	Quantitative detection of grey and white matter amyloid pathology using a combination of K114 and CRANAD-3 fluorescence. Neurobiology of Disease, 2021, 161, 105540.	2.1	8
189	Cognitive interventions and performance measures: a longitudinal study in elderly women. Estudos De Psicologia (Campinas), 0, 37, .	0.8	1
191	Centenarians as Models of Resistance and Resilience to Alzheimer's Disease and Related Dementias. Advances in Geriatric Medicine and Research, 2020, 2, .	0.6	8
195	Design, Synthesis, biological investigations and molecular interactions of triazole linked tacrine glycoconjugates as Acetylcholinesterase inhibitors with reduced hepatotoxicity. Bioorganic Chemistry, 2022, 118, 105479.	2.0	13
196	Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer's disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12
197	Anatomically Standardized Detection of MRI Atrophy Patterns in Early-Stage Alzheimer's Disease. Brain Sciences, 2021, 11, 1491.	1.1	5
198	Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials. Neurotherapeutics, 2022, 19, 8-25.	2.1	26
199	Barriers to Effective Memory Assessments for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 981-988.	1.2	4

#	ARTICLE	IF	CITATIONS
200	Recent update on the heterogeneity of the Alzheimer's disease spectrum. Journal of Neural Transmission, 2022, 129, 1-24.	1.4	37
202	Association of Alzheimer's Disease with COVID-19 Susceptibility and Severe Complications: A Nationwide Cohort Study. Journal of Alzheimer's Disease, 2022, 87, 701-710.	1.2	13
203	Verbal and Nonverbal Memory in Neurodegenerative and Stroke Aphasia: Evidence From the Turkish Version of the Three Words Three Shapes Test. Cognitive and Behavioral Neurology, 2022, 35, 49-65.	0.5	1
204	Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants. Frontiers in Neuroscience, 2022, 16, 827447.	1.4	4
205	Sensorimotor Synchronization in Healthy Aging and Neurocognitive Disorders. Frontiers in Psychology, 2022, 13, 838511.	1.1	6
206	Alzheimer: A Complex Genetic Background. , 0, , .		0
207	Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data. Emerging Topics in Life Sciences, 2021, 5, 765-777.	1.1	22
208	Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome. Acta Neuropathologica Communications, 2021, 9, 201.	2.4	11
210	Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials. journal of prevention of Alzheimer's disease, The, 0, , 1.	1.5	2
211	Identification of Alzheimer's Disease Molecular Subtypes Based on Parallel Large-Scale Sequencing. Frontiers in Aging Neuroscience, 2022, 14, 770136.	1.7	9
212	Characterizing Differences in Functional Connectivity Between Posterior Cortical Atrophy and Semantic Dementia by Seed-Based Approach. Frontiers in Aging Neuroscience, 2022, 14, 850977.	1.7	2
213	Physical understanding in neurodegenerative diseases. Cognitive Neuropsychology, 2021, 38, 490-514.	0.4	1
214	Autosomal dominant and sporadic late onset Alzheimer's disease share a common *in vivo* pathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
215	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre–Mild Cognitive Impairment. Neurology, 2022, 99, .	1.5	5
217	Role of Hypertension and Hyperlipidemia in the Pathogenesis of Dementia. , 2022, , 251-272.		1
218	Four Distinct Subtypes of Alzheimer's Disease Based on Resting-State Connectivity Biomarkers. Biological Psychiatry, 2023, 93, 759-769.	0.7	20
220	Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	33
221	Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer's Disease. Neurochemical Research, 2023, 48, 13-25.	1.6	7

#	Article	IF	Citations
222	Proteomic Markers and Early Prediction of Alzheimer's Disease. Biochemistry (Moscow), 2022, 87, 762-776.	0.7	2
223	Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer's Disease Risk. Environmental Health Perspectives, 2022, 130, .	2.8	6
224	Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer's disease. Nature Communications, 2022, 13, .	5.8	24
225	Brain microstructure abnormalities in the 3xTg-AD mouse – A diffusion MRI and morphology correlation study. Magnetic Resonance Imaging, 2022, 94, 48-55.	1.0	1
226	Role of Impaired Insulin Signaling in the Pathogenesis of Dementia. , 2022, , 63-84.		0
227	The temporal lobe in typical and atypical Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, , 449-466.	1.0	5
228	Distribution of cortical atrophy associated with cognitive decline in Alzheimer's disease: a cross-sectional quantitative structure MRI study from PUMCH dementia cohort. Current Alzheimer Research, 2022, 19, .	0.7	0
229	The effect of Montessori program in the elderly with dementia: a literature review. , 2022, 20, 249-264.		0
230	Neuroimaging Markers for Determining Former American Football Players at Risk for Alzheimer's Disease. Neurotrauma Reports, 2022, 3, 398-414.	0.5	1
231	Role of neurotransmitters in immune-mediated inflammatory disorders: a crosstalk between the nervous and immune systems. Neurological Sciences, 2023, 44, 99-113.	0.9	5
232	Research on Alzheimer's syndromes is critical to improve diagnosis, patient management and non-pharmacological treatments, but is under-pursued. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
234	Multifunctional Carbon-Dot-Photosensitizer Nanoassemblies for Inhibiting Amyloid Aggregates, Suppressing Microbial Infection, and Overcoming the Blood–Brain Barrier. ACS Applied Materials & Interfaces, 2022, 14, 47432-47444.	4.0	11
235	Associação entre os aspectos genéticos e imunológicos na patogênese do Alzheimer. Revista Neurociencias, 0, 30, 1-19.	0.0	0
236	Differential Gene Expression and DNA Methylation in the Risk of Depression in LOAD Patients. Biomolecules, 2022, 12, 1679.	1.8	1
238	Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research. Translational Psychiatry, 2022, 12, .	2.4	11
239	Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: Methodology review and benchmark. Journal of Biomedical Informatics, 2023, 137, 104256.	2.5	4
240	Diencephalic versus Hippocampal Amnesia in Alzheimer's Disease: The Possible Confabulation-Misidentification Phenotype. Journal of Alzheimer's Disease, 2023, 91, 363-388.	1.2	1
241	A Tutorial for Speech-Language Pathologists: Physical Activity and Social Engagement to Prevent or Slow Cognitive Decline in Older Adults. American Journal of Speech-Language Pathology, 2023, 32, 83-95.	0.9	3

#	ARTICLE	IF	CITATIONS
243	Preliminary exploration of the co-regulation of Alzheimerâ€™s disease pathogenic genes by microRNAs and transcription factors. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
244	Incidence of Parkinson disease in North America. Npj Parkinson's Disease, 2022, 8, .	2.5	47
245	Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimerâ€™s disease related proteins. Molecular Neurodegeneration, 2023, 18, .	4.4	5
246	Omic-Based Biomarkers Discovery in Alzheimerâ€™s Disease: High-Throughput Approaches. , 2023, , 1-18.		0
247	Early prediction of Alzheimer's disease and related dementias using realâ€world electronic health records. Alzheimer's and Dementia, 2023, 19, 3506-3518.	0.4	9
248	Analysis of gene expression profiles in Alzheimerâ€™s disease patients with different lifespan: A bioinformatics study focusing on the disease heterogeneity. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
249	Two Routes to Alzheimerâ€™s Disease Based on Differential Structural Changes in Key Brain Regions. Journal of Alzheimer's Disease, 2023, 92, 1399-1412.	1.2	0
250	Thiopheneâ€Based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphicâ€Diseaseâ€Associated Protein Aggregates. ChemBioChem, 2023, 24, .	1.3	4
252	The Effects of Amyloid-Î² on Metabolomic Profiles of Cardiomyocytes and Coronary Endothelial Cells. Journal of Alzheimer's Disease, 2023, , 1-13.	1.2	1
253	Altered largeâ€scale dynamic connectivity patterns in Alzheimer's disease and mild cognitive impairment patients: A machine learning study. Human Brain Mapping, 2023, 44, 3467-3480.	1.9	3
254	Tau accumulates differently in four subtypes of Alzheimer's disease. Neurology and Clinical Neuroscience, 2023, 11, 231-238.	0.2	0
255	Identification of telomere-related genes associated with aging-related molecular clusters and the construction of a diagnostic model in Alzheimer's disease based on a bioinformatic analysis. Computers in Biology and Medicine, 2023, 159, 106922.	3.9	2
256	Disambiguation of Cognitive Impairment Diagnosis with EEG-Based Dual-Contrastive Learning. , 2023, , .		0
284	Case report: Rapidly progressive neurocognitive disorder with a fatal outcome in a patient with PU.1 mutated agammaglobulinemia. Frontiers in Immunology, 0, 15, .	2.2	0